anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A computer implemented method and system for tracking and managing therapy sessions using a therapy management application (TMA) is provided. The TMA is accessible by an electronic device in multiple access modes. The TMA schedules therapy sessions with multiple clients and generates one or more goals for each of the clients based on an evaluation of the clients in the therapy sessions. The TMA categorizes the generated goals for each of the clients into one or more goal categories and defines one or more goal measurements for each of the generated goals within each of the goal categories. The TMA collects and tracks data acquired from the scheduled therapy sessions of each of the clients for the defined goal measurements via a graphical user interface. The TMA generates progress reports based on performance of each of the clients for each of the generated goals using the collected and tracked data.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to pediatric surgery, and can be used for children with Hirschsprung's disease in perioperative period with antibacterial prevention. Preoperative preparation involves determination of carriers of toxigenic strains C.difficile, for this purpose, admission to the hospital is followed by examination of faeces for toxigenic strains C.difficile. If C.difficile toxins A and B (or A+B) are detected, an antibacterial therapy is prescribed: vancomycin 10 mg/kg for admission 4 times day for 7 days. Simultaneously, a probiotic preparation is administered based on Saccharomyces boulardii 250 mg once day for 7 days. In intraoperative period 60 minutes before the operation, metronidazole 7.5 mg/kg is intravenously administered. 30–40 minutes before the operation intravenous introduction of cefazolin 25 mg/kg. If the surgical intervention is continued for more than 3–4 hours, one more dose of cefazolin is added. Either 120 minutes before the surgical intervention, vancomycin 40 mg/kg is administered. That is followed by intravenous administration of cefazolin 25 mg/kg 30–40 minutes before the operation. If the surgical intervention is continued for more than 3–4 hours, one more dose of cefazolin is added. If observing allergic reactions to beta-lactam antibiotics, a combination of clindamycin 600 mg/kg and gentamycin 5 mg/kg is administered 40–60 minutes prior to surgery. In the presence of infectious complications in the postoperative period, etiotropic antibiotic and a probiotic based on S. boulardii 250 mg once day for 7 days are prescribed. If observing no infectious complications, the antibacterial therapy is not followed, and the S. boulardii-based probiotic is prescribed for 7 days.EFFECT: invention enables reducing a risk of enterocolitis and other infectious complications and reduces length of stay of the patient in a hospital bed.1 cl, 2 ex
PURPOSE: Children with communication disorders are often systematically excluded from sex education curricula. They may also have difficulty accessing the curricula because of the materials' linguistic and pragmatic complexity. Even curricula written for children with intellectual disabilities do not typically include considerations for communication disorders. This places them at risk for sexually transmitted infections, sexual health misinformation, and sexual assault. Yet, it is unclear which professionals are assisting children with communication disorders to access sex education.
METHOD: North American speech-language pathologists (SLPs) and clinical psychologists (N = 112) completed a survey that asked about their practice patterns in helping children access sex education, as well as their beliefs about the importance of sex education, how disabilities affect sex education, perceived barriers, and their self-efficacy and role in addressing sex education.
RESULTS: Although SLPs and clinical psychologists believed that communication disorders could affect sex education and consent and felt they had some responsibility for helping their clients in accessing sex education, they did not regularly assist their clients in this area. Both groups of clinicians were divided in their views of their own roles and responsibility. SLPs were especially polarized; every question about their role in addressing sex education included SLPs who fully agreed and some who fully disagreed with the statement.
CONCLUSIONS: Children with communication disorders do not consistently receive assistance accessing sex education curricula from either SLPs or clinical psychologists. Clinicians need education to support them addressing sex education and clear guidance about their roles in this area.
Cognitive impairment induced by postoperative pain severely deteriorates the rehabilitation outcomes in elderly patients. The present study focused on the relationship between microglial exosome miR-124-3p in hippocampus and cognitive impairment induced by postoperative pain. Cognitive impairment model induced by postoperative pain was constructed by intramedullary nail fixation after tibial fracture. Morphine intraperitoneally was carried out for postoperative analgesia. Morris water maze tests were carried out to evaluate the cognitive impairment, while mRNA levels of neurotrophic factors (BDNF, NG) and neurodegenerative biomarker (VILIP-1) in hippocampus were tested by q-PCR. Transmission electron microscope was used to observe the axon degeneration in hippocampus. The levels of pro-inflammatory factors (TNF-α, IL-1β, IL-6), the levels of anti-inflammatory factors (Ym, Arg-1, IL-10) and microglia proliferation marker cyclin D1 in hippocampus were measured to evaluate microglia polarization. Bioinformatics analysis was conducted to identify key exosomes while BV-2 microglia overexpressing exosome miR-124-3p was constructed to observe microglia polarization in vitro experiments. Exogenous miR-124-3p-loaded exosomes were injected into hippocampus in vivo. Postoperative pain induced by intramedullary fixation after tibial fracture was confirmed by decreased mechanical and thermal pain thresholds. Postoperative pain induced cognitive impairment, promoted axon demyelination, decreased BDNF, NG and increased VILIP-1 expressions in hippocampus. Postoperative pain also increased pro-inflammatory factors, cyclin D1 and decreased anti-inflammatory factors in hippocampus. However, these changes were all reversed by morphine analgesia. Bioinformatics analysis identified the critical role of exosome miR-124-3p in cognitive impairment, which was confirmed to be down-regulated in hippocampus of postoperative pain mice. BV-2 microglia overexpressing exosome miR-124-3p showed decreased pro-inflammatory factors, cyclin D1 and increased anti-inflammatory factors. In vivo, stereotactic injection of exogenous miR-124-3p into hippocampus decreased pro-inflammatory factors, cyclin D1 and increased anti-inflammatory factors. The cognitive impairment, axon demyelination, decreased BDNF, NG and increased VILIP-1 expressions in hippocampus were all alleviated by exogenous exosome miR-124-3p. Microglial exosome miR-124-3p in hippocampus alleviates cognitive impairment induced by postoperative pain through microglia polarization in elderly mice.
A hallmark of cancer is the avoidance of immune destruction. This process has been primarily investigated in locally advanced or metastatic cancer1-3; however, much less is known about how pre-malignant or early invasive tumours evade immune detection. Here, to understand this process in early colorectal cancers (CRCs), we investigated how naive colon cancer organoids that were engineered in vitro to harbour Apc-null, KrasG12D and Trp53-null (AKP) mutations adapted to the in vivo native colonic environment. Comprehensive transcriptomic and chromatin analyses revealed that the endoderm-specifying transcription factor SOX17 became strongly upregulated in vivo. Notably, whereas SOX17 loss did not affect AKP organoid propagation in vitro, its loss markedly reduced the ability of AKP tumours to persist in vivo. The small fraction of SOX17-null tumours that grew displayed notable interferon-γ (IFNγ)-producing effector-like CD8+ T cell infiltrates in contrast to the immune-suppressive microenvironment in wild-type counterparts. Mechanistically, in both endogenous Apc-null pre-malignant adenomas and transplanted organoid-derived AKP CRCs, SOX17 suppresses the ability of tumour cells to sense and respond to IFNγ, preventing anti-tumour T cell responses. Finally, SOX17 engages a fetal intestinal programme that drives differentiation away from LGR5+ tumour cells to produce immune-evasive LGR5- tumour cells with lower expression of major histocompatibility complex class I (MHC-I). We propose that SOX17 is a transcription factor that is engaged during the early steps of colon cancer to orchestrate an immune-evasive programme that permits CRC initiation and progression.
Chest masculinization surgery is an increasingly common procedure and has offered significant benefits to the gender-diverse community. Although major complications are an infrequent occurrence in chest masculinization surgery, they may still impact surgical success. While the long-term success of chest masculinization surgery has been examined through patient-reported outcome measures, there is no study that has assessed the association between complications and patient-reported outcomes. In this study, patients who underwent double incision or periareolar mastectomies for chest masculinization by a single surgeon were surveyed. Demographic, operative, and postoperative variables were obtained from medical records. The BODY-Q and SCAR-Q modules (Q-Portfolio.org) were used to assess postoperative patient-reported outcomes. There were 151 survey responders (43% response rate), 132 without complications and 19 with complications. No significant differences in patient-reported outcomes were noted when comparing the groups with and without complications. While some providers may be reluctant to offer chest masculinization to patients they deem high risk for complications, patients and providers should be assured that complications do not significantly impact patient satisfaction. LAY SUMMARY: Gender-affirming chest masculinization surgery is increasingly common. We investigated the impact of complications on patient-reported outcomes in chest masculinization. Patients and providers should be assured that complications do not significantly impact patient satisfaction.
Our project proposes to address gaps in functionality of commercially available EHR systems through evaluation of novel, EHR-integrated HIT tools. We previously designed, developed, and implemented the patient safety dashboard and interactive pre-discharge checklist to engage clinicians and patients in systematically addressing safety threats in each of several domains. By integrating clinical data of several different types, these tools serve to reduce cognitive load and improve decision-making for clinicians. In this way, these tools represent a preventative intervention that mitigates risk in each domain by suggesting corrective action corresponding to institutional safety guidelines.

Studying the effectiveness of these tools on post-discharge outcomes will improve knowledge, technical capability, and clinical practice related to patient safety during transitions of care. Specifically, our project will advance scientific knowledge by quantifying the post-discharge impact of an intervention that changes clinical practice by enabling hospital-based clinicians to proactively institute corrective action for "at risk" patients who may require additional surveillance and supportive services during transitions. Also, we will establish the technical feasibility of spreading customized, third-party digital health applications that fill critical safety gaps in commercially available EHRs; expanding to a community hospital has clear implications for adoption and validation of this technology in different practice settings.
This study will involve 2 regimens which will run in parallel. Each participant's upper back will be divided into 2 equal spaces for Regimen 1 and 2. Each of the 4 treatment sites in each space will be independently randomized to placebo or rHuPH20 treatment in a 1:1 ratio. Thus, each participant will serve as their own control. Regimen 1 will evaluate the treatment of cutaneous reactions to nickel and Regimen 2 will evaluate the prevention as well as the treatment of cutaneous reactions to nickel. At screening, the nickel sulfate concentration (1%, 2.5%, or 5%) applied to the skin of the upper back with a patch, that will cause no more than a ++ reaction according to the scale of the International Contact Dermatitis Research Group (ICDRG) will be determined. This concentration will be used to elicit cutaneous reactions during the study period.
The present invention provides antimicrobial skin-preparations useable to disinfect a surgical site for surgery. The antimicrobial skin-preparation formula includes iodine, alcohol and gel. The new pre-operative skin-preparation quickly and effectively kills microorganisms when applied to the surgical site. The skin-preparation continues to effectively inhibit microorganism growth in the applied area over an extended period of time. One gel skin-preparation according to the invention includes alcohol at 60 % - 90 % v/v, iodine at 1.0 % - 15.0 % w/v, and gel at 0.1 % - 30.0 % w/v. A carrier solvent and other optional components may also be added to the formula.
Abstract of Research Proposal:

Breast cancer is a heterogeneous disease, with various subtypes demonstrating differing biological behavior, prognosis, and response to therapeutic agents. Improving the understanding of the biology of breast cancer can result in better prognostication and therapy in individual patients, and has important clinical implications. While valuable scientific knowledge is generated from studies of breast cancer cell lines or animal models, such information generated in vitro may not fully reflect the in vivo model. Direct analysis of patient samples is important to validate in vitro findings, and represents a step closer to clinical application. Studying patient tumor samples for genetic and protein markers and correlating these analyses with clinical characteristics and outcomes could provide valuable insights into tumor biology in vivo, and leads to better understanding of tumor biology and resistance mechanisms. This is a single-centre study of biomarker analysis in breast tumors. A total of 400 patients with breast lesions for whom a diagnostic core biopsy is planned will be enrolled over 2 years. During the diagnostic tumor core biopsy, 3-4 additional tumor samples will be obtained through the same needle track for the purpose of this study. The tumor cores will be stored in liquid nitrogen for subsequent histopathological analysis; DNA, RNA and protein will be extracted from tumor cores for genetic, gene expression and proteomics studies. The patient's clinical progress will be tracked through the clinical case files. For patients in whom the clinical diagnostic biopsy yields a benign result, the samples obtained from them will serve as control specimens. For patients in whom the clinical diagnostic core biopsy confirms the diagnosis of breast cancer, the samples will be considered cases, and the following information will be tracked: histopathological characteristics of the tumor including ER/PR/c-erbB2 status and other known prognostic and predictive immunohistochemical markers (e.g., Ki67, p53, etc), anti-cancer treatment, progression-free and overall survival.
PROBLEM TO BE SOLVED: To obtain the subject injection controlled in coloring and stable by including vancomycin and an organic acid in water. SOLUTION: This injection of vancomycin, adjusted at a pH 3.00 to 3.40 for use and sealed with an inert gas, e.g. nitrogen, helium, argon or the like in the final production stage, is obtained by including (A) 90 to 99.8 wt.% of vancomycin, preferably in the form of salt with a free body, hydrochloric acid, nitric acid or the like, (B) 0.2 to 5 wt.% of an organic acid as an aliphatic hydrocarbon having a hydroxide group and ether bond, which has a carboxyl group or ionized body in the molecule, and shows an acidic pH level (e.g. acetic acid, propionic acid, butanoic acid, tartaric acid, citric acid or the like), and (C) an optional ingredient, in addition to the above essential ingredients, e.g. a buffer agent or the like of sodium citrate, potassium citrate, sodium hydrogen phosphate or the like, wherein the above percentages are based on the water-free composition.  It is preferably freeze-dried, and administered at a dosage of 100 to 2000 mg.
Dosage adjustment must be made in patients with renal impairment. The initial dose should be no less than 15 mg/kg, in patients with any degree of renal impairment.

In premature infants and the elderly, greater dosage reductions than expected may be necessary because of decreased renal function. Measure trough vancomycin serum concentrations to guide therapy, especially in seriously ill patients with changing renal function.  


For functionally anephric patients, an initial dose of 15 mg/kg of body weight should be given to achieve prompt therapeutic serum concentration. A dose of 1.9 mg/kg/24 hr should be given after the initial dose of 15 mg/kg.
A method for preparing a conjugate, and preferably a protein-polysaccharide conjugate, includes functionalizing a first moiety (e.g., a polysaccharide) with one or more pendant haloacyl groups. Thereafter, the functionalized first moiety is reacted with a second moiety, preferably an unmodified protein or a protein to which no thiol groups have been added, to form a covalently linked conjugate. Various different haloacyl reagents can be used in the invention.  For example, the haloacyl reagent can be an active ester, an anhydride, a haloacyl chloride, or a haloacyl acid. Specific haloacyl reagents that can be used in the process of the invention include N-succinimidyl-2,3-dibromopropionate and N-succinimidyl iodoacetate. The invention further relates to the conjugates produced by the method of the invention. These conjugates can be used as immunogens or vaccines. Furthermore, the invention also relates to a method of inducing an immune response in a subject by administering a vaccine made by the method according to the inventtion.
PURPOSE: A patient with primary CoQ10 deficiency associated with the c.901 C > T (p.R301W) (rs140246430) homozygous missense pathogenic variant in the COQ8A gene, who presented with recurrent status epilepticus, stroke-like lesions, and hypertrophic cardiomyopathy while being followed-up with early-onset autosomal recessive cerebellar ataxia will be reported in this article.
CASE REPORT: A 16-year-old patient who was being followed up at an external center with a diagnosis of ataxia with cerebellar atrophy had been seen 3 different times within a year for status epilepticus. The cerebral MRI showed severe cerebellar atrophy, stroke like lesions, and an inverted double- lactate peak on spectroscopy. Her echocardiography revealed marked left ventricular hypertrophy. Mitochondrial cocktail therapy containing a standard dose of CoQ10 was started, considering mitochondrial disease. The patient died due to cardiomyopathy. Mitochondrial panel analysis revealed the presence of the c.901 C > T (p.R301W) homozygous missense mutation in the COQ8A gene.
CONCLUSIONS: Primary Coenzyme Q10 deficiency should be considered in patients presenting with autosomal recessive stable-appearing progressive ataxia, emerging attacks of status epilepticus, stroke-like lesions on neuroimaging, and cardiomyopathy. Since there is a case with the same mutation with a similar fatal course in the literature, detection of c.901 C > T (p.R301W) mutation homozygously should be a warning for a severe prognosis and more aggressive treatment should be started without delay with a high dose of CoQ10 instead of the lower doses used in the treatment of mitochondrial disease.
Antibody-directed targeting of chemotherapeutic nanoparticles to primary human cancers holds promise for improving efficacy and reducing off-target toxicity. However, clinical responses to targeted nanomedicines are highly variable. Herein, we prepared and examined a matrix of 9 particles (organic and inorganic particles of three surface chemistries with and without antibody functionalization) and developed an ex vivo model to study the person-specific targeting of nanoparticles in whole blood of 15 patients with chronic lymphocytic leukemia (CLL). Generally, anti-CD20-functionalized poly(ethylene glycol) (PEG) nanoparticles efficiently targeted CLL cells, leading to low off-target phagocytosis by granulocytes and monocytes in the blood. However, there was up to 164-fold patient-to-patient variability in the CLL targeting. This was further exemplified through using clinically relevant PEGylated doxorubicin-encapsulated liposomes, which showed high interpersonal differences in CLL targeting (up to 234-fold differences) and off-target phagocytosis (up to 65- and 112-fold differences in granulocytes and monocytes, respectively). Off-target phagocytosis led to almost all monocytes being killed within 24 h of treatment. Variance of the off-target association of PEGylated liposomes with granulocytes and monocytes significantly correlated to anti-PEG immunoglobulin G levels in the blood of CLL patients. A negative correlation between CLL targeting of PEG particles and anti-PEG immunoglobulin M levels was found in the blood. Taken together, our study identifies anti-PEG antibodies as key proteins in modulating patient-specific targeting of PEGylated nanoparticles in human leukemia blood. Other factors, such as the antigen expression of targeted cells and fouling properties of nanoparticles, also play an important role in patient-specific targeting. The human leukemia blood assay we developed provides an ex vivo model to evaluate interpersonal variances in response to targeted nanomedicines.
The invention discloses a traditional Chinese medicine composition with functions of reducing fat and losing weight. The traditional Chinese medicine composition consists of the following raw materials in parts by weight: 20-30 parts of rhizoma atractylodis macrocephalae, 20-30 parts of semen cassiae, 20-30 parts of fried hawthorn, 20-30 parts of tangerine peel, 10-20 parts of radix stephaniae tetrandrae, 10-20 parts of radix salviae miltiorrhizae, 10-20 parts of liquorice, 5-15 parts of folium artemisiae argyi, 5-15 parts of cornu bubali and 5-15 parts of ramulus cinnamomi. The traditional Chinese medicine composition is orally taken, twice per day and 10-20g each time. Generally after taking the composition for one month or so, the weight is obviously reduced; and after about three months, the weight can be basically reduced to the standard weight. The traditional Chinese medicine composition with functions of reducing fat and losing weight, disclosed by the invention, does not bring obvious side effect or cause anorexia, nausea, no appetite and the like after taking. The raw materials are cheap and easily available, and the cost is relatively low. The traditional Chinese medicine composition has a good curative effect and takes an effect quickly; and 57 patients suffering obesity are treated, wherein the weight of 49 patients is obviously reduced within three months, and the effective rate is about 86%.